LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Languages: English
Types: Article
Subjects:
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] Foex B. A. How the cholera epidemic of 1831 resulted in a new technique for uflid resuscitation. Emergency Medicine Journal 2003; 20(4): 316-318.
    • [2] Brunkhorst F. M., Engel C., Bloos F., Meier-Hellmann A., Ragaller M., Weiler N., Moerer O., Gruendling M., Oppert M., Grond S., Olthoff D., Jaschinski U., John S., Rossaint R., Welte T., Schaefer M., Kern P., Kuhnt E., Kiehntopf M., Hartog C., Natanson C., Loefeflr M., Reinhart K. and S. German Competence Network. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358(2): 125-139.
    • [3] Myburgh J. A., Finfer S., Bellomo R., Billot L., Cass A., Gattas D., Glass P., Lipman J., Liu B., McArthur C., McGuinness S., Rajbhandari D., Taylor C. B., Webb S. A., C. Investigators, Australian and G. New Zealand Intensive Care Society Clinical Trials. Hydroxyethyl starch or saline for uflid resuscitation in intensive care. N Engl J Med 2012; 367(20): 1901-1911.
    • [4] Perner A., Haase N., Guttormsen A. B., Tenhunen J., Klemenzson G., Aneman A., Madsen K. R., Moller M. H., Elkjaer J. M., Poulsen L. M., Bendtsen A., Winding R., Steensen M., Berezowicz P., SoeJensen P., Bestle M., Strand K., Wiis J., White J. O., Thornberg K. J., Quist L., Nielsen J., Andersen L. H., Holst L. B., Thormar K., Kjaeldgaard A. L., Fabritius M. L., Mondrup F., Pott F. C., Moller T. P., Winkel P., Wetterslev J., S. T. Group and G. Scandinavian Critical Care Trials. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367(2): 124-134.
    • [5] Mazzaferro E. and Powell L. L. Fluid therapy for the emergent small animal patient: crystalloids, colloids, and albumin products. Vet Clin North Am Small Anim Pract 2013; 43(4): 721-734.
    • [6] Wellman M.L ., DiBartola D. S., Kohn C.W. Applied physiology of body uflids in dogs and cats. In: DiBartola SP editors. Fluid, electrolyte, and acid-base disorders in small animal practice. St. Louis (MO): Saunders Elsevier; 2006 p 3-26.
    • [7] Mensack S. Fluid therapy: options and rational administration. Vet Clin North Am Small Anim Pract 2008; 38(3): 575-586, xi.
    • [8] Chan D. L. Colloids: current recommendations. Vet Clin North Am Small Anim Pract 2008; 38(3): 587-593, xi.
    • [9] Ertmer C., Rehberg S., Van Aken H. and Westphal M. Relevance of non-albumin colloids in intensive care medicine. Best Pract Res Clin Anaesthesiol 2009; 23(2): 193-212.
    • [10] Hughes D. Fluid therapy with articfiial colloids: complications and controversies. Veterinary Anaesthesia and Analgesia 2001; 28(2).
    • [11] Wierenga J. R., Jandrey K. E., Haskins S. C. and Tablin F. In vitro comparison of the effects of two forms of hydroxyethyl starch solutions on platelet function in dogs. Am J Vet Res 2007; 68(6): 605-609.
    • [12] Smart L., Jandrey K. E., Kass P. H., Wierenga J. R. and Tablin F. The effect of Hetastarch (670/0.75) in vivo on platelet closure time in the dog. J Vet Emerg Crit Care 2009; 19(5): 444-449.
    • [13] Chohan A. S., Greene S. A., Grubb T. L., Keegan R. D., Wills T. B. and Martinez S. A. Effects of 6% hetastarch (600/0.75) or lactated Ringer's solution on hemostatic variables and clinical bleeding in healthy dogs anesthetized for orthopedic surgery. Vet Anaesth Analg 2011; 38(2): 94-105.
    • [14] Falco S., Bruno B., Maurella C., Bellino C., D'Angelo A., Gianella P., Tarducci A., Zanatta R. and Borrelli A. In vitro evaluation of canine hemostasis following dilution with hydroxyethyl starch (130/0.4) via thromboelastometry. J Vet Emerg Crit Care 2012; 22(6): 640-645.
    • [15] McBride D., Hosgood G. L., Mansefild C. S. and Smart L. Effect of hydroxyethyl starch 130/0.4 and 200/0.5 solutions on canine platelet function in vitro. Am J Vet Res 2013; 74(8): 1133-1137.
    • [16] Vineyard G. C., Bradley B. E., Defalco A., Lawson D., Wagner T. A., Pastis W. K., Nardella F. A. and Hayes J. R. Effect of hydroxyethyl starch on plasma volume and hematocrit following hemorrhagic shock in dogs: comparison with dextran, plasma and Ringer's. Ann Surg 1966; 164(5): 891-899.
    • [17] Mailloux L., Swartz C. D., Capizzi R., Kim K. E., Onesti G., Ramirez O. and Brest A. N. Acute renal failure after administration of low-molecular weight dextran. N Engl J Med 1967; 277(21): 1113-1118.
    • [18] Jamal R., Ghannoum M., Naud J.F., Turgeon P.P., Leblanc M. Permanent renal failure induced by pentastarch. NDT Plus 2008; 5: 322-325.
    • [19] Huter L., Simon T. P., Weinmann L., Schuerholz T., Reinhart K., Wolf G., Amann K. U. and Marx G. Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage inlfitration and tubular damage in an isolated renal perfusion model Crit Care 2009; 13(1): R23.
    • [20] Legendre C., Thervet E., Page B., Percheron A., Noel L. H. and Kreis H. Hydroxyethylstarch and osmoticnephrosis-like lesions in kidney transplantation. Lancet 1993; 342(8865): 248-249.
    • [21] Haase N. and Perner A. Hydroxyethyl starch for resuscitation. Curr Opin Crit Care 2013; 19(4): 321- 325.
    • [22] Westphal M., James M. F., Kozek-Langenecker S., Stocker R., Guidet B.and Van Aken H. Hydroxyethyl starches: different products--different effects. Anesthesiology 2009; 111(1): 187-202.
    • [23] Perel P. and Roberts I. Colloids versus crystalloids for ulfid resuscitation in critically ill patients. Cochrane Database Syst Rev 2007; (4): CD000567.
    • [24] Reinhart K. and Takala J. Hydroxyethyl starches: what do we still know? Anesth Analg 2011; 112(3): 507- 511.
    • [25] Dellinger R. P., Levy M. M., Rhodes A., Annane D., Gerlach H., Opal S. M., Sevransky J. E., Sprung C. L., Douglas I. S., Jaeschke R., Osborn T. M., Nunnally M. E., Townsend S. R., Reinhart K., Kleinpell R. M., Angus D. C., Deutschman C. S., Machado F. R., Rubenfeld G. D., Webb S. A., Beale R. J., Vincent J. L., Moreno R.and S. Surviving Sepsis Campaign Guidelines Committee including the Pediatric. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(2): 580-637.
    • [26] Perel P., Roberts I. and Ker K. Colloids versus crystalloids for uflid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013; 2: CD000567.
    • [27] Mutter T. C., Ruth C. A. and Dart A. B. Hydroxyethyl starch (HES) versus other uflid therapies: effects on kidney function. Cochrane Database Syst Rev 2013; 7: CD007594.
    • [28] European Medicines Agency. 2013 EMA/349341/2013: PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch. Retrieved December, 2013, from http://www.ema.europa.eu/docs/en_GB/ document_library/Referrals_document/Solutions_ for_infusion_containing_hydroxyethyl_starch/ Recommendation_provided_by_Pharmacovigilance_ Risk_Assessment_Committee/WC500144448.pdf.
    • [29] U.S. Food and Drug Administration. Hydroxyethyl Starch Solutions: FDA Safety Communication - Boxed Warning on Increased Mortality and Severe Renal Injury and Risk of Bleeding. Retrieved December, 2013, from http://www. fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm358349. htm.
    • [30] European Medicines Agency. EMA/809470/2013: Hydroxyethyl-starch solutions (HES) no longer to be used in patients with sepsis or burn injuries or in critically ill patients. Retrieved March, 2014, from http://www.ema.europa.eu/docs/en_GB/document_ library/Referrals_document/Hydroxyethyl_starchcontaining_medicines_107/European_Commission_ nifal_decision/WC500162428.pdf.
    • [31] Diomi P., Matheson N. A., Norman J. N., Robertson J. W. and Shearer J. R. Effects of dextran 40 on urine olfw and composition during pronounced reduction in renal perfusion. Eur Surg Res 1969; 1(1): 20-25.
    • [32] Driessen B., Jahr J. S., Lurie F., Golkaryeh M. S. and Gunther R. A. Arterial oxygenation and oxygen delivery after hemoglobin-based oxygen carrier infusion in canine hypovolemic shock: a doseresponse study. Crit Care Med 2003; 31(6): 1771-1779.
    • [33] Driessen B., Jahr J. S., Lurie F. and Gunther R. A. Effects of isovolemic resuscitation with hemoglobinbased oxygen carrier Hemoglobin glutamer-200 (bovine) on systemic and mesenteric perfusion and oxygenation in a canine model of hemorrhagic shock: a comparison with 6% hetastarch solution and shed blood. Vet Anaesth Analg 2006; 33(6): 368-380.
    • [34] Haak C. E., Rudloff E. and Kirby R. Comparison of Hb-200 and 6% hetastarch 450/0.7 during initial ulfid resuscitation of 20 dogs with gastric dilatationvolvulus. J Vet Emerg Crit Care 2012; 22(2): 201-210.
    • [35] Weingart C. and Kohn B. Clinical use of a haemoglobin-based oxygen carrying solution (Oxyglobin) in 48 cats (2002-2006). J Feline Med Surg 2008; 10(5): 431-438.
    • [36] Finfer S. Reappraising the role of albumin for resuscitation. Curr Opin Crit Care 2013; 19(4): 315- 320.
    • [37] Trow A. V., Rozanski E. A., Delaforcade A. M. and Chan D. L. Evaluation of use of human albumin in critically ill dogs: 73 cases (2003-2006). J Am Vet Med Assoc 2008; 233(4): 607-612.
    • [38] Vigano F., Perissinotto L. and Bosco V. R. Administration of 5% human serum albumin in critically ill small animal patients with hypoalbuminemia: 418 dogs and 170 cats (1994- 2008). J Vet Emerg Crit Care 2010; 20(2): 237-243.
    • [39] Cohn L. A., Kerl M. E., Lenox C. E., Livingston R. S. and Dodam J. R. Response of healthy dogs to infusions of human serum albumin. Am J Vet Res 2007; 68(6): 657-663.
    • [40] Silverstein D. C., Aldrich J., Haskins S. C., Drobatz K. J. and Cowgill L. D. Assessment of changes in blood volume in response to resuscitative uflid administration in dogs. J Vet Emerg Crit Care 2005; 15(3): 185-192.
    • [41] Barros J. M., do Nascimento P., Marinello Jr. J. L., Braz L. G., Carvalho L. R., Vane L. A., Castiglia Y. M. and Braz J. R. The effects of 6% hydroxyethyl starch-hypertonic saline in resuscitation of dogs with hemorrhagic shock. Anesth Analg 2011; 112(2): 395- 404.
    • [42] Jacob M. and Chappell D. Reappraising Starling: the physiology of the microcirculation. Curr Opin Crit Care 2013; 19(4): 282-289.
    • [43] Myburgh J. A. and Mythen M. G. Resuscitation uflids. N Engl J Med 2013; 369(13): 1243-1251.
    • [44] Woodcock T. E. and Woodcock T. M. Revised Starling equation and the glycocalyx model of transvascular ulfid exchange: an improved paradigm for prescribing intravenous uflid therapy. Br J Anaesth 2012; 108(3): 384-394.
    • [45] Morgan T. J. The ideal crystalloid - what is 'balanced'? Curr Opin Crit Care 2013; 19(4): 299-307.
    • [46] Yunos N. M., Kim I. B., Bellomo R., Bailey M., Ho L., Story D., Gutteridge G. A. and Hart G. K. The biochemical effects of restricting chloride-rich uflids in intensive care. Crit Care Med 2011; 39(11): 2419- 2424.
    • [47] Shaw A. D., Bagshaw S. M., Goldstein S. L., Scherer L. A., Duan M., Schermer C. R. and Kellum J. A. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. Ann Surg 2012; 255(5): 821-829.
    • [48] Yunos N. M., Bellomo R., Hegarty C., Story D., Ho L. and Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous uflid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308(15): 1566-1572.
    • [49] Boyd J. H., Forbes J., Nakada T. A., Walley K. R. and Russell J. A. Fluid resuscitation in septic shock: a positive uflid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011; 39(2): 259-265.
    • [50] Murphy C. V., Schramm G. E., Doherty J. A., Reichley R. M., Gajic O., Afessa B., Micek S. T. and Kollef M. H. The importance of uflid management in acute lung injury secondary to septic shock. Chest 2009; 136(1): 102-109.
    • [51] Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M.. Early oal-Directed Therapy Collaborative: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345(19): 1368-1377.
    • [52] Peng Z. Y. and Kellum J. A. Perioperative uflids: a clear road ahead? Curr Opin Crit Care 2013; 19(4): 353-358.
    • [53] Marik P. E., Baram M. and Vahid B. Does central venous pressure predict uflid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008; 134(1): 172-178.
    • [54] Monnet X. and Teboul J. L. Assessment of volume responsiveness during mechanical ventilation: recent advances. Crit Care 2013; 17(2): 217.
    • [55] Perel A., Pizov R. and Cotev S. Systolic blood pressure variation is a sensitive indicator of hypovolemia in ventilated dogs subjected to graded hemorrhage. Anesthesiology 1987; 67(4): 498-502.
    • [56] Berkenstadt H., Friedman Z., Preisman S., Keidan I., Livingstone D.and Perel A. Pulse pressure and stroke volume variations during severe haemorrhage in ventilated dogs. Br J Anaesth 2005; 94(6): 721-726.
    • [57] Conti-Patara A., de Araujo Caldeira J., de MattosJunior E., de Carvalho Hda S., Reinoldes A., Pedron B. G., Patara M., Francisco Talib M. S., Faustino M., de Oliveira C. M. and Cortopassi S. R. Changes in tissue perfusion parameters in dogs with severe sepsis/septic shock in response to goal-directed hemodynamic optimization at admission to ICU and the relation to outcome. J Vet Emerg Crit Care 2012; 22(4): 409-418.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article